In a stunning transfer, the Supreme Courtroom rejected a bid by a Bristol Myers Squibb unit to reinstate a $1.2 billion award it gained in a contentious patent combat with a Gilead Sciences subsidiary over the profitable marketplace for gene therapies.
Nevertheless, the choice got here simply days after the Supreme Courtroom agreed to evaluation a really related case involving Amgen and two different drugmakers, which primarily entails the identical subject, however comes at it from a unique authorized perspective.
